These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 36199183

  • 1. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
    Li W, Chen Q, Gao W, Zeng H.
    Pharmazie; 2022 Sep 01; 77(7):224-229. PubMed ID: 36199183
    [Abstract] [Full Text] [Related]

  • 2. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R, Thomson JM, Govindarajan R.
    PLoS One; 2013 Sep 01; 8(1):e53436. PubMed ID: 23335963
    [Abstract] [Full Text] [Related]

  • 3. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M, Li H, Lv N, Xi C, Lu Z, Wei J, Chen J, Guo F, Jiang K, Song G, Gao W, Miao Y.
    Mol Cancer; 2017 Mar 21; 16(1):66. PubMed ID: 28327155
    [Abstract] [Full Text] [Related]

  • 4. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H, Lu S, Yang D, Zhang L, Ye J, Li M, Hu W.
    Biosci Rep; 2019 May 31; 39(5):. PubMed ID: 30777929
    [Abstract] [Full Text] [Related]

  • 5. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
    Oncogene; 2004 Feb 26; 23(8):1539-48. PubMed ID: 14661056
    [Abstract] [Full Text] [Related]

  • 6. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
    Liu Q, Song C, Li J, Liu M, Fu L, Jiang J, Zeng Z, Zhu H.
    Med Oncol; 2022 Jun 18; 39(9):124. PubMed ID: 35716217
    [Abstract] [Full Text] [Related]

  • 7. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X.
    J Exp Clin Cancer Res; 2017 Aug 10; 36(1):107. PubMed ID: 28797284
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
    Clin Cancer Res; 2004 Apr 01; 10(7):2307-18. PubMed ID: 15073106
    [Abstract] [Full Text] [Related]

  • 9. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS.
    Carcinogenesis; 2014 Oct 01; 35(10):2203-13. PubMed ID: 24879635
    [Abstract] [Full Text] [Related]

  • 10. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 11. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
    Lewis CS, Voelkel-Johnson C, Smith CD.
    Oncotarget; 2016 Sep 13; 7(37):60181-60192. PubMed ID: 27517489
    [Abstract] [Full Text] [Related]

  • 12. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG, Atay S, Aydin HH, Ak H.
    Anticancer Agents Med Chem; 2021 Oct 28; 21(16):2204-2215. PubMed ID: 33397269
    [Abstract] [Full Text] [Related]

  • 13. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 28; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 14. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ.
    J Exp Clin Cancer Res; 2014 Dec 12; 33(1):102. PubMed ID: 25499121
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M.
    Anticancer Res; 2008 Dec 12; 28(4B):2205-12. PubMed ID: 18751396
    [Abstract] [Full Text] [Related]

  • 16. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
    Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K.
    J Gastroenterol; 2007 May 12; 42(5):389-94. PubMed ID: 17530364
    [Abstract] [Full Text] [Related]

  • 17. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H, Lin J, Thomas DG, Jiang W, Liu X.
    Int J Clin Exp Pathol; 2012 May 12; 5(4):347-55. PubMed ID: 22670179
    [Abstract] [Full Text] [Related]

  • 18. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
    Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J.
    PLoS One; 2008 May 12; 3(11):e3695. PubMed ID: 19002265
    [Abstract] [Full Text] [Related]

  • 19. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
    Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ, Giovannetti E.
    Nucleosides Nucleotides Nucleic Acids; 2014 May 12; 33(4-6):384-93. PubMed ID: 24940696
    [Abstract] [Full Text] [Related]

  • 20. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
    Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL.
    J Biol Chem; 2018 Jan 19; 293(3):984-994. PubMed ID: 29191829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.